Our current study provided novel insights into the mechanisms underlying ER+ BC drug resistance and demonstrated that PFKFB4 plays an essential role during tumour cell stemness transformation and acquired CDK4/6 inhibitor resistance. The gene discussed is CDK4; the disease is breast cancer.